APG-157 is under clinical development by Aveta Biomics and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Recurrent Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how APG-157’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APG-157 is under development for the treatment of recurrent high-grade glioma squamous cell carcinoma of oral cavity and oropharynx, recurrent glioblastoma multiforme accessible for local and topical administration, anaplastic astrocytoma, anaplastic oligodendroglioma and gliosarcoma. It is also under treatment for head and neck squamous cell cancer (HNSCC) of the oral cavity and/or oropharynx The drug candidates are developed as network modulating drugs. They are administered through oral route and topical route.
Aveta Biomics overview
Aveta Biomics., is a developer of a pain relief medicine that designed to help users recover headaches and body-aches. The company is headquartered in United States.
For a complete picture of APG-157’s drug-specific PTSR and LoA scores, buy the report here.